A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Conditions: Cervical Cancer Interventions: Drug: Disitamab Vedotin; Drug: Zimberelimab Sponsors: RemeGen Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials